

Pr

Dantrium® IV

dantrolene sodium for injection

USP 20mg

Dantrium® (dantrolene sodium) Intravenous is indicated in the management of a malignant hyperthermia crisis. Please refer to the product monograph for full prescribing information available at www.dantrium.ca

Four necessary steps to prepare for a **Malignant Hyperthermia Crisis**

1

Stock a minimum of 36 vials of Dantrium® IV^{1,2}

The recommended stock for facilities administering trigger agents is a minimum of 36 vials of Dantrium® IV. According to MHAUS (Malignant Hyperthermia Association of the United States), MH may be triggered by specific potent inhalation gas anesthetics (please see reverse). MHAUS also states that succinylcholine, a depolarizing muscle relaxant, is a known MH trigger. Therefore, in facilities where succinylcholine is used, Dantrium® IV should be available.

2

Place Dantrium® IV in a central location^{1,2}

MHAUS suggests that facilities have these vials available within five minutes of the onset of an MH event, so your department/facility should place in a central location where staff can retrieve Dantrium® IV in under five minutes.²

3

Gather sterile water for injection and other necessary drugs and equipment for stabilization^{1,2}

For a complete list of MHAUS suggestions, please view their brochure "Drugs, Equipment, and Dantrolene - Managing MH" updated in 2008, available at www.mhaus.org.

4

Train and drill¹

MHAUS recommends that all facilities where MH triggering agents are administered stock a minimum 36 vials of Dantrium® IV (a typical 71 kg patient may require up to 36 vials to achieve the therapeutic dose of Dantrium® IV for the MH crisis to resolve).² All such facilities should also be prepared to treat an MH crisis within 5 minutes of its onset.²



MHAUS Malignant Hyperthermia Hotline
for MH Crisis Management and Case Reporting
In USA and Canada 1 - 800 - 644 - 9737 or 315 - 464 - 7079

References:

1 Four Steps to Prepare for Malignant Hyperthermia - Becker's ASC Review Website. www.beckersasc.com
2 Adapted from the Malignant Hyperthermia Association of the United States Website. www.mhaus.org.
(see For Medical Professionals - FAQs) Accessed 03/18/09

Dantrium® is distributed in Canada by Methapharm Inc. and is a registered trade-mark of JHP Pharmaceuticals, L.L.C.

methapharm®
specialty products • innovative solutions

Tel. 519.751.3602 • 1.800.287.7686 • Fax 519.751.9149
www.methapharm.com • sales@methapharm.com

DANIV-4pts-Sept09E

Pr

Dantrium® IV

dantrolene sodium for injection

USP 20mg

Dantrium® (dantrolene sodium) Intravenous is indicated in the management of a malignant hyperthermia crisis. Please refer to the product monograph for full prescribing information available at www.dantrium.ca

MH triggering Agents¹

Inhaled General Anesthetics

- Desflurane
- Enflurane
- Halothane
- Isoflurane
- Methoxyflurane
- Sevoflurane

Depolarizing Muscle Relaxants

- Succinylcholine

Number of vials of Dantrium® IV (20 mg/vial) needed to treat an MH crisis²

Patient's Weight:		Number of vials* of Dantrium® IV required to achieve the following concentrations based on the patient's weight:				
kg	lbs	[1 mg/kg]	[2.5 mg/kg]	[5 mg/kg]	[7.5 mg/kg]	[10 mg/kg]
45	99	3	6	12	17	23
58	128	3	8	15	22	29
73	161	4	10	19	28	37
88	194	5	11	22	33	44
103	227	6	13	26	39	52
118	260	6	15	30	45	59
133	293	7	17	34	50	67
148	326	8	19	37	56	74

 = greater than 36 vials required
* rounded up to the nearest whole vial

Calculations made using 20 mg vials of Dantrium® IV (dantrolene sodium for injection) reconstituted with 60 mL of sterile water (without a bacteriostatic agent)



MHAUS Malignant Hyperthermia Hotline
for MH Crisis Management and Case Reporting
In USA and Canada 1 - 800 - 644 - 9737 or 315 - 464 - 7079

methapharm®

specialty products • innovative solutions

Tel. 519.751.3602 • 1.800.287.7686 • Fax 519.751.9149
www.methapharm.com • sales@methapharm.com

REFERENCES:

1 Adapted from the Dantrium® IV Product Monograph.
2 Adapted from the Malignant Hyperthermia Association of the United States website: www.mhaus.org (see For Medical Professionals-Anesthetics). Accessed 05/01/09.

Dantrium® is distributed in Canada by Methapharm Inc. and is a registered trade-mark of JHP Pharmaceuticals, L.L.C.